Equibles does not estimate personal net worth.
Get an email with a short summary when Twist Bioscience Corp publishes a filing, an earnings call transcript or a press release.
Get TWST alertsAdam Laponis is recorded as CFO at Twist Bioscience Corp (TWST). The newest filing on record that lists Adam Laponis as CFO at Twist Bioscience Corp (TWST) is dated January 6, 2026. Twist Bioscience Corp reported in an 8-K filed January 5, 2024 that Adam Laponis was appointed Chief Financial Officer, effective January 8, 2024. The proxy statement of Twist Bioscience Corp reports total compensation of $4,216,117 for Adam Laponis in fiscal 2025, including a base salary of $490,000. Disclosed compensation is on record for 2 fiscal years. Adam Laponis has spoken on 11 earnings calls and 1 other investor event across 1 company, most recently for Twist Bioscience Corp on September 15, 2026. Twist Bioscience Corp is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Twist Bioscience Corp includes Emily Leproust (CEO), Patrick Finn (COO), Patrick Weiss (COO) and 7 others.
“On January 5, 2024, Twist Bioscience Corporation (the "Company") announced the appointment of Adam Laponis as the Company's Chief Financial Officer and principal financial officer, effective January 8, 2024.”
“On the diagnostic side, yes, that's right. On the therapeutic side, I think it was the question. We did see a flat quarter and quarter, but about 49% year over year growth.”
“Turning to slide 14, Q3 was another quarter of consistent execution against the financial model we've laid out. Revenue grew 23% year-over-year to $118.4 million, our 14th consecutive quarter of sequential growth.”
“Turning to slide 12, Q2 is another quarter of consistent execution against the financial model we've laid out. Revenue grew 19.3% year-over-year to $110.7 million, our 13th consecutive quarter of sequential growth.”
“Revenue for the first quarter increased to $103.7 million. Growth is 17% year-over-year and approximately 5% sequentially.”
“Revenue for the fourth quarter increased to $99 million, growth of 17% year-over-year and approximately 3% sequentially. For fiscal 2025, revenue increased to $376.6 million, growth of 20% year-over-year.”
Start not stated–present
Last confirmed January 6, 2026
Biotechnology · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Twist Bioscience Corp (TWST) | Chief Financial Officer | $490,000 | $4,216,117 |
| 2024 | Twist Bioscience Corp (TWST) | Chief Financial Officer | $330,708 | $5,008,244 |
